BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,197,187 | -17.9% | 235,009 | -46.4% | 0.02% | -10.0% |
| Q2 2023 | $7,544,832 | +59.6% | 438,653 | +53.9% | 0.02% | +33.3% |
| Q1 2023 | $4,726,875 | +538268.5% | 285,095 | +146.8% | 0.02% | +275.0% |
| Q4 2022 | $878 | -99.9% | 115,537 | -29.1% | 0.00% | -42.9% |
| Q3 2022 | $1,619,000 | -44.4% | 162,880 | -44.6% | 0.01% | +40.0% |
| Q2 2022 | $2,912,000 | +71.9% | 293,970 | +88.7% | 0.01% | 0.0% |
| Q1 2022 | $1,694,000 | -55.2% | 155,811 | -31.3% | 0.01% | -50.0% |
| Q4 2021 | $3,785,000 | -64.8% | 226,857 | +0.8% | 0.01% | -63.0% |
| Q3 2021 | $10,746,000 | -21.1% | 224,979 | +0.7% | 0.03% | -22.9% |
| Q2 2021 | $13,616,000 | -0.8% | 223,463 | +0.1% | 0.04% | +12.9% |
| Q1 2021 | $13,729,000 | +4357.5% | 223,214 | +5055.1% | 0.03% | +3000.0% |
| Q4 2020 | $308,000 | -40.1% | 4,330 | -68.4% | 0.00% | 0.0% |
| Q3 2020 | $514,000 | – | 13,698 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |